MRI Muscle in Tumors and Infection — Generic Standard Protocol

MRIninja Knowledge Base | Master / General Protocol Page Anatomical domain: peripheral and deep skeletal muscle and adjacent soft tissues (limbs, girdle, and trunk musculature) Version 1.0 — July 2026

1. Executive Summary

MRI is the reference-standard cross-sectional modality for the local evaluation of a suspected soft-tissue mass or a suspected deep soft-tissue infection involving skeletal muscle. Its superior soft-tissue contrast resolution, multiplanar capability, and ability to characterise tissue composition (fat, fluid, fibrous tissue, haemorrhage, necrosis) and enhancement pattern make it markedly more informative than ultrasound for deep or large lesions, and than CT for local staging, even though ultrasound remains the appropriate first-line triage tool for small, superficial, easily accessible lesions and CT retains a defined role for gas detection, calcification, cortical bone involvement and in patients unable to undergo MRI ultrasound remains the best initial triage imaging modality for accessible and small suspected soft tissue tumors, MRI is the modality of choice for the characterization and local staging of soft tissue tumors in most cases, and CT is indicated in special situations.

This generic master page covers the common technical backbone shared by two distinct but frequently co-referred clinical scenarios that both present as a painful, swollen, or palpable abnormality of skeletal muscle and its surrounding soft tissue:

• Soft-tissue tumors — benign and malignant, including soft-tissue sarcoma and intramuscular/perimuscular metastases;
• Soft-tissue infection — cellulitis, soft-tissue/intramuscular abscess, pyomyositis, necrotizing soft-tissue infection (necrotizing fasciitis), and other inflammatory collections.

These two categories share an almost identical acquisition backbone (multiplanar fluid-sensitive fat-suppressed sequences, T1-weighted anatomical sequences, and — critically, unlike the trauma-oriented muscle protocol on this platform — a central, non-optional role for gadolinium-enhanced imaging), which justifies grouping them on a single generic master page. Their downstream management pathways diverge sharply, however, which is why this page routes toward dedicated child protocols once a specific diagnosis is suspected (e.g., a dedicated soft-tissue sarcoma staging protocol including chest CT and, where indicated, whole-body MRI, or a dedicated necrotizing-fasciitis pathway that is fundamentally a surgical emergency rather than an imaging-driven diagnosis).

This generic protocol is designed to answer the broad first-line question: “is there a discrete mass, and does it have soft-tissue-sarcoma-suspicious features requiring further work-up?” or “is there a fluid collection/abscess, and is there any feature raising concern for a necrotizing or rapidly progressive process?” It is not designed to:

• provide a definitive histological diagnosis (image-guided or open biopsy remains the diagnostic reference standard for most indeterminate soft-tissue masses);
• perform whole-body oncological staging (a dedicated staging protocol, following ESSR guidance, is required once a sarcoma is confirmed or strongly suspected);
• substitute for emergency clinical and surgical assessment in a patient with clinical features of a necrotizing soft-tissue infection — this remains fundamentally a surgical emergency, and imaging must never delay surgical exploration when the clinical picture is already convincing;
• characterise chronic myopathy, inflammatory myositis, or muscular dystrophy, which follow a separate, largely non-contrast, often whole-body or bilateral comparative pathway;
• replace the dedicated muscle-trauma protocol for a straightforward strain/tear, where contrast is not routinely required (see the companion “MRI Muscle in Trauma and Mechanical Disorders” master page).

1.1 Core strengths

• Superior soft-tissue contrast for lesion detection, internal characterisation (fat, cystic/necrotic, haemorrhagic, myxoid, fibrous components) and delineation of the anatomical compartment(s) involved, which underpins local staging of both tumors and infective collections.
• Multiplanar imaging depicts relationships to the neurovascular bundle, adjacent bone, and fascial compartments — information that is central to both surgical planning for a sarcoma and to determining the depth and extent of an infective process.
• Gadolinium-enhanced imaging discriminates solid enhancing tissue from non-enhancing necrosis or simple fluid, which is the single most useful feature separating a drainable abscess from solid infected/inflamed tissue, and separating a hypervascular mass from a largely cystic/myxoid one.
• Diffusion-weighted imaging (DWI)/ADC mapping provides an increasingly used, contrast-independent adjunct for characterising cellularity and for distinguishing viable tumor from necrosis or from a fluid collection.

1.2 Intrinsic limitations of the generic protocol

A generic protocol for this broad indication group is a compromise between breadth, acquisition time, and diagnostic specificity, and this compromise is more consequential here than in purely traumatic imaging, because both oncological and infective differential diagnoses carry high clinical stakes.

• Neither MRI feature set is fully specific: benign and malignant soft-tissue masses overlap substantially in signal characteristics, and a definitive “benign versus malignant” determination by imaging alone is frequently not possible; a comprehensive characterisation strategy including size, depth, growth pattern, necrosis, and enhancement pattern is used to stratify risk, but tissue sampling remains the reference standard for a large proportion of indeterminate lesions.
• MRI has real but bounded accuracy for necrotizing soft-tissue infection: a systematic review found that the most widely used MRI criterion (T2 hyperintensity of the deep fascia) has high sensitivity but only moderate specificity for necrotizing soft-tissue infection T2 hyperintensity of deep fascia at MRI has high sensitivity and moderate specificity in diagnosing necrotizing soft tissue infection, meaning that a negative MRI substantially reduces suspicion, but a positive finding does not by itself confirm the diagnosis, and clinical severity/LRINEC-type scoring and surgical judgement retain a central role.
• Time-critical infections must not be delayed by elective-style imaging workflow: when the clinical picture already strongly suggests a necrotizing process, imaging — if performed at all — must be expedited and must not substitute for, or delay, surgical exploration.
• Contrast is central to this protocol group, in contrast to the muscle-trauma master page; this has direct implications for patient preparation, renal function screening, and acquisition workflow that are specific to this indication group and must be planned for at the point of referral, not improvised at the scanner.
• A generic small-to-moderate field of view centred on the palpable abnormality may under-sample a second, non-contiguous lesion (relevant to metastatic disease and to multifocal or tracking infective collections along fascial planes), and a whole-body or wide-field complement is a distinct, dedicated workflow rather than an extension of this generic protocol.

2. Main Clinical Indications

2.1 Standard Indications

The generic protocol is appropriate as the first dedicated cross-sectional local-imaging study for the large majority of referrals in this indication group: a palpable soft-tissue mass of uncertain nature within or adjacent to skeletal muscle; a soft-tissue swelling with clinical or laboratory features suggestive of infection (fever, elevated inflammatory markers, localised warmth/erythema) where the depth and extent of involvement is unclear on clinical examination or ultrasound; suspected intramuscular abscess or pyomyositis, particularly when deep or difficult to assess by ultrasound; suspected cellulitis with clinical uncertainty about deeper extension; and known extra-muscular malignancy with a new soft-tissue lesion raising concern for a metastasis. In each of these scenarios, the generic contrast-enhanced multiplanar protocol usually answers the immediate question — presence, extent, and basic tissue characterisation of the abnormality, and the degree of concern that warrants further action (biopsy, drainage, urgent surgical referral, or oncological staging). A dedicated child protocol becomes necessary once the generic study establishes a specific diagnostic direction: confirmed or strongly suspected soft-tissue sarcoma requires a dedicated local-staging-plus-whole-body-staging pathway; a clinical picture dominated by systemic sepsis and rapidly progressive soft-tissue findings should not wait for a full diagnostic MRI work-up at all, but proceed to emergency surgical assessment; and known or biopsy-confirmed lymphoma, myeloma, or a specific sarcoma subtype (e.g., myxoid liposarcoma, rhabdomyosarcoma) benefits from an entity-specific staging algorithm rather than the generic protocol alone.

2.2 Urgent Red Flags Requiring Expedited or Emergency Imaging

Unlike simple muscle trauma, this indication group includes presentations that can be genuinely life- or limb-threatening within hours, and the red-flag section below is clinically substantial rather than a formality.

3. Preparation Reference

Universal MRI safety screening (implants, devices, claustrophobia) and the universal gadolinium contrast safety questionnaire belong to the general MRI preparation page and are not repeated here in full; the region- and indication-specific items below should be added on top of that universal screening.

3.1 Anatomy-Specific Preparation Items

• Renal function / GBCA eligibility screening should be anticipated at referral, not only at the scanner, because contrast is central rather than optional for this indication group; departments should ensure eGFR status is available before the appointment whenever local policy requires it, to avoid an incomplete, non-contrast-only study for a question that specifically requires contrast.
• Skin marker at the palpable abnormality or the point of maximal clinical concern: essential for correct FOV centring, exactly as for the trauma protocol, and arguably even more important here because masses and collections are frequently deep and may not correspond precisely to the area of visible skin change (e.g., in cellulitis, the visible erythema may extend well beyond, or fall short of, the deep abnormality).
• Documentation of any prior biopsy, aspiration, or surgical intervention at the site: post-biopsy haemorrhage/oedema, seeding tracts, and post-surgical change materially alter interpretation and must be known before the study is read; whenever possible, imaging should be planned before biopsy, since post-biopsy change can complicate assessment of tumor margins and can mimic infection or interval growth.
• Metal near the region: relevant both for artefact planning and, in suspected infection following orthopaedic hardware placement, for anticipating a periprosthetic/hardware-related pattern of infection that may require metal-artefact-reduction sequences.
• Compression garments/bandaging and wound dressings: should be removed for coil placement when clinically safe to do so; document if a dressing cannot be removed, since this may introduce artefact or limit skin-surface assessment.
• Coil selection: flexible surface/phased-array coils are preferred for limb lesions; for large trunk or girdle masses, a torso/body coil combination may be required, with attention to maintaining adequate signal-to-noise across the full extent of a large lesion.
• Patient history that changes the protocol: known primary malignancy elsewhere (raises pre-test probability of metastasis and may justify earlier oncological-pathway referral); immunosuppression or diabetes (alters the threshold of concern for an aggressive or necrotizing infective process); intravenous drug use at or near the imaged site (raises pre-test probability of abscess/pyomyositis and of an atypical organism).

3.2 Patient Positioning on the MRI System

• Position: supine for the great majority of limb, girdle, and trunk lesions; positioning is otherwise dictated by lesion location rather than by a single anatomical default, unlike the more standardised muscle-trauma protocol.
• Coil selection and centring: the coil and field of view should be centred on the marked lesion/collection, with coverage extended generously beyond the palpable margin, since both tumors and infective collections frequently extend beyond their clinically apparent boundary — a narrow FOV strictly matched to palpable margins is a common and consequential planning error in this indication group.
• Immobilisation: as for trauma imaging, but with particular attention to patient comfort in the presence of a painful infective or malignant mass; adequate analgesia before scanning materially improves image quality and reduces the need for a repeat study.
• Anatomical alignment: symmetric limb positioning is valuable when a contralateral comparison is planned (frequently useful in both infection — comparing affected and unaffected limb muscle signal/enhancement — and in tumor imaging when baseline anatomical variants need to be excluded).
• Comfort strategies: patients with an acute infective process or a painful mass may not tolerate a long protocol; sequence prioritisation (Section 8) should be planned in advance for this group more than for routine trauma referrals.
• Common positioning errors: FOV too tightly restricted to the palpable or visibly inflamed area, missing proximal/distal extension along fascial planes or missing a second lesion; failure to include a comparison region when contralateral comparison would aid interpretation; scanning through a dressing that displaces the coil.
• Practical technologist checks before starting: confirm laterality; confirm the marked region is centred and adequately covered with margin; confirm contrast eligibility has been checked and consent obtained before starting the non-contrast portion of the study, so that the protocol is not interrupted partway through.

4. Standard Protocol Design

4.1 Mandatory Core Sequences

4.2 Conditional Sequences

4.3 Rationale Summary Per Sequence

T1-weighted non-fat-suppressed sequences provide the anatomical roadmap and are particularly informative for fat content (diagnostic for a lipomatous lesion), for haemorrhage, and for delineating the lesion against the normal fat planes that typically outline a soft-tissue mass, since a mass that infiltrates and obliterates the normal fat plane is a feature that raises concern for malignancy or for an aggressive infective process. In infection, unenhanced T1 gives a useful low-signal baseline against which post-contrast enhancement is compared.

Fluid-sensitive fat-suppressed T2/STIR sequences are the most sensitive sequences for detecting both a mass (typically T2-hyperintense relative to muscle, though signal is heterogeneous and not by itself diagnostic of a specific entity) and an infective/inflammatory process (muscle oedema in pyomyositis, fascial hyperintensity in fasciitis, and the fluid signal of an abscess or cellulitis-associated fluid). The main pitfall is that T2 signal alone does not reliably separate tumor from infection or from post-traumatic change, and that oedema can extend well beyond the causative lesion, again risking overestimation of the extent of the “true” abnormality if enhancement characteristics are not also assessed.

Pre- and post-contrast fat-suppressed T1-weighted sequences are the diagnostic core of this protocol group and the principal feature distinguishing it from the muscle-trauma master page. Enhancement pattern is central to risk-stratifying a mass (solid enhancing components versus non-enhancing cystic/necrotic/myxoid components; peripheral versus diffuse enhancement; presence of enhancing septations) and is the single most useful discriminator between a drainable abscess (rim enhancement around a non-enhancing, typically restricted-diffusion fluid centre) and solid infected/inflamed tissue that is not amenable to simple drainage the presence of rim-enhancing soft-tissue abscesses facilitates the diagnosis of an infectious rather than an inflammatory process. A pre-contrast fat-suppressed T1 sequence is required so that intrinsically T1-hyperintense content (fat, subacute blood, proteinaceous fluid) is not misread as enhancement on the post-contrast images; without a matched pre-contrast baseline, subtraction or confident visual comparison is not possible.

Diffusion-weighted imaging/ADC is an increasingly used adjunct rather than a mandatory sequence at this stage of adoption: restricted diffusion favours a cellular, viable-tumor or a purulent/abscess component, while free diffusion favours simple fluid, myxoid tissue, or necrosis, and this distinction supports both oncological characterisation and infective work-up, particularly in patients in whom contrast cannot be given.

4.5 Fat Suppression, Contrast-Specific or Region-Specific Technical Modifiers

Fat suppression is required on both the fluid-sensitive T2 sequence and, critically, on the pre- and post-contrast T1-weighted sequences, since unsuppressed post-contrast T1 images are difficult to interpret against the bright background of adjacent subcutaneous and intermuscular fat. As with the trauma protocol, three techniques are available:

• Spectral fat saturation is the routine default for a well-centred, moderate FOV at both field strengths, and is generally adequate for limb lesions.
• STIR should be used, rather than spectral fat saturation, whenever homogeneous suppression cannot be guaranteed — large or asymmetric FOV, curved trunk/girdle contours, off-isocentre lesions, or nearby metal — but STIR must not be used after contrast administration; STIR is contraindicated post-gadolinium because of unpredictable, paradoxical suppression behaviour that can obscure or falsify true enhancement. The pre-contrast fat-suppressed T1 and the post-contrast fat-suppressed T1 in this protocol must therefore both use spectral fat saturation or Dixon-based fat suppression, never STIR.
• Dixon-based fat/water separation is a strong modern option for this indication group specifically, because it can generate matched pre- and post-contrast fat-only, water-only and “in-phase”/“out-of-phase” images from a single acquisition, which is efficient and provides an inherently well-matched dataset for enhancement assessment; department-dependent adoption.

Field-strength issues broadly mirror those described for the trauma protocol; at 3 T, the wider chemical-shift separation improves spectral fat suppression and Dixon separation, at some cost in SAR for longer fat-saturated sequences, which is a more relevant constraint here given the larger number of fat-suppressed acquisitions (pre- and post-contrast) required in this protocol relative to the trauma protocol.

4.6 Slice Positioning — Complete Technical Reference

Why slice positioning matters

Correct positioning in this indication group serves two purposes that differ subtly from the trauma protocol: first, ensuring the full craniocaudal and cross-sectional extent of a mass or collection is captured, including any extension along fascial planes or into an adjacent compartment that changes surgical or interventional planning; second, ensuring that pre- and post-contrast sequences are acquired with identical geometry, since enhancement assessment depends on this matching far more critically than trauma-oriented T1/T2 comparison does.

Planning sequence

Plan from the three-plane localiser and, where available, from any prior imaging (ultrasound, CT, previous MRI) that already localises the abnormality; centre the initial overview sequence on the marked skin site, then extend coverage generously (typically several centimetres beyond the palpable or sonographically defined margin) before committing to the final small-FOV, contrast-matched acquisition plan.

Axial planning

• Axial slices should be planned perpendicular to the long axis of the limb or of the lesion itself when the lesion has a clear long axis (as with many intramuscular tumors and elongated abscess collections), rather than defaulting to a fixed anatomical plane.
• Coverage must extend generously beyond the visible or palpable margin of the abnormality — for a mass, at least enough to include a clear margin of normal tissue on all sides for accurate size and compartment assessment; for an infective collection, enough to capture any tracking along fascial planes, which is a key determinant of whether a process is localised or has features suggestive of a more extensive/necrotizing process.
• Slice thickness in the range of approximately 3–5 mm is a reasonable working default for a moderate-to-large lesion; thinner sections with a smaller FOV are preferred for small or deep lesions where fine internal characterisation (septations, small necrotic foci, thin rim enhancement) is diagnostically important.

Sagittal / coronal (long-axis) planning

• A long-axis overview plane (sagittal or coronal, chosen according to lesion orientation) should capture the full craniocaudal extent of the abnormality, including its relationship to adjacent joints, major vessels, and named nerves, since this information is frequently what determines whether the lesion is amenable to straightforward biopsy/drainage or requires specialist surgical or interventional planning.
• For girdle and trunk lesions, coronal planning is often more informative for overall compartmental relationships, while sagittal planning better displays anteroposterior extent relative to named structures.

Oblique planning

An oblique plane aligned to the long axis of an elongated or fascial-plane-tracking lesion (e.g., a collection tracking along an intermuscular septum) is not part of the mandatory core protocol but adds diagnostic value whenever the standard orthogonal planes leave ambiguity about the precise compartment(s) involved.

Coverage limits

Coverage should be tailored to the region of clinical concern, generously extended as above, but a request for suspected multifocal disease (metastases, or infective tracking suspected to be extensive) should prompt an explicit wide-FOV or whole-limb sequence rather than an ad hoc extension of the small-FOV protocol — see Section 4.2.

Phase-encoding considerations

As in the trauma protocol, phase-encoding direction should generally be set along the shorter FOV dimension; for lesions adjacent to major vessels, anticipate and, where necessary, mitigate pulsation artefact with saturation bands or an adjusted phase-encoding direction, since vascular pulsation artefact projecting across a mass or collection can mimic internal heterogeneity or a septation.

How to verify symmetry

For infective processes where contralateral comparison is planned, confirm that the unaffected side is imaged with matched geometry and, ideally, in the same examination session, since muscle signal and enhancement baseline vary enough between separate sessions/positions to compromise a delayed comparison.

Common errors

FOV restricted to the visibly/palpably abnormal area without margin, missing extension along fascial planes; mismatched geometry between pre- and post-contrast sequences, precluding reliable subtraction or visual comparison; omission of a pre-contrast fat-suppressed T1 sequence, precluding confident distinction between intrinsic T1-hyperintensity and true enhancement; failure to extend coverage to a named adjacent joint or neurovascular bundle when the lesion approaches it.

Serial follow-up reproducibility

For oncological surveillance and for monitoring a treated infective collection, document and reproduce coil type, FOV, and slice geometry at follow-up; this is particularly important for lesion-size and enhancement-volume comparison over time, which underpins both sarcoma surveillance and infective-collection resolution monitoring.

Automated planning tools

As with the trauma protocol, automated limb-imaging planning tools are not yet a validated substitute for manual, lesion-tailored planning by an experienced technologist in this anatomical region.

Bibliography for this section

5. Optimisation Strategy

5.1 Artifact Reduction by Source

5.2 Protocol Efficiency and Throughput

A “premium” protocol — additional planes, DWI/ADC, dynamic contrast-enhanced acquisition, and finer in-plane resolution — is justified whenever the clinical question is oncologically significant (a mass with any suspicious feature) or when a collection’s drainability needs precise characterisation before an interventional procedure. A shortened protocol — the core axial and one long-axis fluid-sensitive sequence plus the matched pre/post-contrast T1 fat-suppressed pair — is appropriate for the more routine referral where the primary question is “characterise this palpable abnormality and flag any concerning feature.” Three-dimensional acquisition has a more defensible role in this protocol group than in trauma imaging, particularly for post-contrast imaging of larger or trunk-based masses where isotropic reformatting aids surgical planning; nonetheless, 2D multiplanar imaging remains the practical default for most routine referrals, with 3D reserved for cases where reconstruction flexibility offers a clear planning benefit.

5.3 Field Strength Considerations

At 3 T, improved signal-to-noise supports either higher resolution or shorter acquisition of the multiple fat-suppressed pre/post-contrast sequences this protocol requires, and Dixon-based fat/water separation benefits from the wider chemical-shift separation. Susceptibility artefact is more pronounced at 3 T, which is relevant when haemorrhage, gas, or metal is present within or near the lesion, and SAR becomes a more binding constraint given the larger number of fat-saturated sequences typically acquired in this protocol compared with trauma imaging. At 1.5 T, DWI is generally more robust to susceptibility-related distortion, which can be a practical advantage for lesions containing haemorrhage or adjacent to gas/metal. The departmental choice between field strengths is again usually dictated by scanner and coil availability rather than a strong universal preference for this indication group.

6. Contrast Use Principles Specific to Muscle Tumors and Infection

Universal GBCA safety screening (renal function thresholds, nephrogenic systemic fibrosis risk assessment, allergy history) belongs to the general MRI preparation page and is not repeated here; the project standard of macrocyclic agents applies. Unlike the muscle-trauma master page, contrast is a central, near-default component of this protocol group rather than a selectively indicated adjunct.

6.1 Non-Contrast Standard Protocol — Sufficient For

A small subset of referrals can be adequately answered without contrast: a lesion with unequivocal, diagnostic non-enhanced signal characteristics of a simple benign entity (e.g., a classic subcutaneous or intramuscular lipoma with pure fat signal and no atypical feature on T1/T2), or an examination performed specifically to exclude a mass where a subsequent normal or clearly benign non-contrast appearance obviates the need to proceed to contrast administration. Contrast is also reasonably deferred in a patient in whom it is contraindicated or unavailable, accepting the resulting reduction in diagnostic confidence, particularly for infective collections where DWI/ADC can partially substitute for enhancement-based characterisation.

6.2 Gadolinium Indicated — Region-Specific Contexts

Gadolinium should be administered as a routine, near-default component of this protocol for: any soft-tissue mass without unequivocally benign non-contrast features, to characterise enhancement pattern and internal architecture and to support risk stratification and biopsy planning; any suspected soft-tissue/intramuscular abscess or pyomyositis, where rim-enhancement characterisation is central to distinguishing a drainable collection from solid infected/inflamed tissue; and any suspected necrotizing soft-tissue infection where imaging is being obtained without delaying surgical assessment, since enhancement pattern of the deep fascia and adjacent muscle contributes incremental diagnostic information beyond T2 signal alone.

6.3 Post-Contrast Acquisition Timing

For mass characterisation, standard early post-contrast imaging (typically within the first few minutes after injection) is sufficient for routine structural and enhancement-pattern assessment; dedicated dynamic contrast-enhanced (time-resolved) imaging is reserved for selected oncological protocols where perfusion kinetics add specific value (Section 4.2) rather than being part of the generic mandatory protocol. For abscess characterisation, early post-contrast imaging reliably demonstrates the rim-enhancement pattern that supports the diagnosis; delayed imaging is not routinely required. Injection time and the timing of each post-contrast sequence relative to injection should be documented, since this is relevant both to the interpretation of enhancement pattern and to reproducibility on any follow-up study.

7. Reporting Essentials

7.1 Interpretation Framework

The report should reason through several complementary axes: acute versus chronic; focal (discrete mass or collection) versus diffuse (diffuse infiltrative process or extensive cellulitis/fasciitis); inflammatory/infective versus neoplastic versus, less commonly in this indication group, vascular or traumatic; intra-compartment versus extra-compartment/transcompartmental extension, which is directly relevant to both surgical planning for a mass and to assessing the severity of an infective process; enhancing versus non-enhancing components, which is central to both tumor characterisation (solid versus necrotic/cystic/myxoid) and to infective-collection characterisation (drainable fluid versus solid inflamed tissue); and incidental versus clinically relevant findings.

7.2 Mandatory Reporting Checklist

The report should not omit: precise anatomical location and compartment(s) involved, with explicit statement of relationship to adjacent bone, major vessels, and named nerves; size in three dimensions; internal characterisation (solid, cystic/necrotic, fat-containing, haemorrhagic) and enhancement pattern; for a mass, an explicit statement of the level of concern (e.g., “no suspicious feature,” “indeterminate, biopsy recommended,” “features suspicious for malignancy, urgent referral recommended”) rather than only a descriptive account; for a suspected infective process, an explicit statement of whether a drainable collection is present and its accessibility for image-guided or surgical drainage, and whether any feature raises concern for a necrotizing process requiring urgent surgical communication; technical limitations (motion, incomplete fat suppression, coverage gaps, absence of contrast if not given and why); comparison with any prior imaging; and explicit critical-result communication whenever a finding requires urgent clinical action.

7.3 Structured Reporting

Reports should follow the standard structure of indication, technique (including whether and when contrast was given), comparison, findings, impression, and limitations, with a dedicated, unambiguous statement of urgency/next step for both a suspicious mass and a possible necrotizing infective process — these two categories should never be left as a purely descriptive finding without an explicit recommendation.

7.4 Incidental Findings — Clinical Decision Framework

• Usually benign: a small, well-defined, pure-fat lesion with no atypical feature (typical lipoma); small, simple ganglion- or bursa-type fluid collections unrelated to the clinical question; minor post-surgical or post-traumatic change from a remote, known prior event.
• Follow-up may be needed: a small indeterminate soft-tissue nodule without a clearly benign signature, particularly if incompletely characterised because it lay outside the optimised small field of view; a small fluid collection of uncertain infective versus non-infective nature in a patient without a corresponding acute clinical picture.
• Urgent or clinically important: any lesion with size, depth, growth pattern, necrosis, or enhancement features suspicious for a soft-tissue sarcoma; unexpected imaging features suggestive of a necrotizing process in a patient whose clinical presentation had not raised this specific concern, which should prompt immediate direct communication with the referring/surgical team rather than routine reporting turnaround.

8. MRI Technologist Pearls

8.1 Sequence Order Logic

Acquire the non-contrast fluid-sensitive and T1-weighted sequences first to establish baseline anatomy and to confirm that the contrast-enhanced portion of the protocol will be geometrically matched and adequately planned before contrast is given, since contrast cannot be “re-given” mid-protocol if the operator later realises the FOV was mis-centred. In an acutely unwell or painful patient, prioritise the sequences most likely to answer the immediate clinical question (typically the fluid-sensitive sequence and the post-contrast fat-suppressed T1) ahead of secondary overview planes.

8.2 Positioning Tricks

Mark and generously bracket the region of interest before final FOV selection, given the tendency of both tumors and infective collections to extend beyond their clinically apparent margin; for suspected bilateral or comparative assessment in infection, consider whether a single wider-FOV acquisition including both limbs is more efficient and better matched than two separate studies.

8.3 Fast Salvage Protocol

If the patient cannot tolerate further imaging, sequences 1–3 together represent the practical minimum for a clinically useful, reportable study in this indication group; omitting the pre-contrast fat-suppressed T1 (sequence 2) should be avoided whenever possible, since it materially degrades confidence in interpreting the post-contrast images.

8.4 Common Avoidable Errors

9. Quality Control Checklist

• Full coverage of the lesion/collection with generous margin beyond the palpable or visible abnormality, confirmed before the patient leaves the scanner.
• Pre- and post-contrast fat-suppressed T1 sequences acquired with matched geometry, enabling reliable comparison or subtraction.
• STIR not used on any post-contrast sequence.
• No significant motion degradation, particularly of the matched pre/post-contrast pair.
• Fat suppression homogeneous across the lesion; STIR or Dixon substituted pre-contrast where spectral technique is inadequate.
• Correct laterality and orientation labelling, verified against the request and the skin marker.
• Contrast administration and injection timing documented.
• Comparison with prior studies performed where available.
• DWI/ADC or other derived maps reviewed for quality if acquired as an adjunct sequence.
• An explicit statement of urgency/next step present in the report draft for any suspicious mass or possible necrotizing infective feature before the study is finalised.

11. Evidence Gaps & Ongoing Debate

• MRI specificity for necrotizing soft-tissue infection remains only moderate: the most widely used criterion (deep fascial T2 hyperintensity) is sensitive but not specific, and no single MRI feature or combination has been definitively validated to replace clinical and surgical judgement; combined criteria (e.g., MRI-integrated LRINEC-type scores) are an active area of research but not yet a settled standard.
• Optimal role and timing of MRI relative to surgical exploration in suspected necrotizing infection is not standardised and is largely guided by local clinical pathways and severity of presentation rather than high-level comparative trial evidence.
• Role of DWI/ADC as a routine, rather than adjunct, sequence for both tumor characterisation and abscess/pyomyositis evaluation is promising but not yet established as mandatory.
• 2D versus 3D post-contrast acquisition for local tumor staging is increasingly debated, with 3D offering reconstruction flexibility at a time/SAR cost; comparative outcome evidence specific to routine clinical practice (rather than technical feasibility) is limited.
• Whole-body/multifocal survey thresholds: criteria for when a generic local study should be extended to a wider or whole-body survey (for suspected metastatic disease, or for suspected extensive fascial tracking of infection) are largely based on expert practice rather than a validated, universally adopted threshold.
• AI-assisted lesion segmentation and enhancement-curve analysis are active areas of technical development, with growing evidence for locally recurrent sarcoma detection, but not yet standard clinical practice across this broad indication group.

12. Evidence-Based References

A. Guidelines / Consensus / Society Recommendations

B. Systematic Reviews / Meta-analyses

C. Important Prospective / Original Studies

5. Kim MC, Kim S, Cho EB, Lee GY, Choi SH, Kim SO, Chung JW. Utility of magnetic resonance imaging for differentiating necrotizing fasciitis from severe cellulitis: a Magnetic Resonance Indicator for Necrotizing Fasciitis (MRINEC) Algorithm. J Clin Med. 2020;9(9):3040. DOI: 10.3390/jcm9093040. Evidence category: C. Evidence label: Moderate. Original derivation of a combined MRI scoring approach for necrotizing fasciitis versus cellulitis.
6. Yoon MA, Chung HW, Yeo Y, Yoo HJ, Kang Y, Chee CG, Lee MH, Lee SH, Shin MJ. Distinguishing necrotizing from non-necrotizing fasciitis: a new predictive scoring integrating MRI in the LRINEC score. Eur Radiol. 2019;29(7):3414–3423. DOI: 10.1007/s00330-019-06103-0. PMID: 30887193. Evidence category: C. Evidence label: Moderate. Original prospective data integrating MRI features with a clinical laboratory score.
7. Kim KT, Kim YJ, Won Lee J, Kim YJ, Park SW, Lim MK, Suh CH. Can necrotizing infectious fasciitis be differentiated from nonnecrotizing infectious fasciitis with MR imaging? Radiology. 2011;259(3):816–824. DOI: 10.1148/radiol.11101164. PMID: 21406630. Evidence category: C. Evidence label: Moderate. Original comparative imaging-feature data underlying current MRI diagnostic criteria for necrotizing infection.
8. Seok JH, Jee WH, Chun KA, Kim JY, Jung CK, Kim YR, Eo WK, Kim YS, Chung YG. Necrotizing fasciitis versus pyomyositis: discrimination with using MR imaging. Korean J Radiol. 2009;10(2):121–128. DOI: 10.3348/kjr.2009.10.2.121. PMID: 19270857. Evidence category: C. Evidence label: Moderate. Original comparative data on enhancement-pattern differences between necrotizing fasciitis and pyomyositis, used in Section 10.

D. Technical MRI Papers

9. Chaudhry AA, Baker KS, Gould ES, Gupta R. Necrotizing fasciitis and its mimics: what radiologists need to know. AJR Am J Roentgenol. 2015;204(1):128–139. DOI: 10.2214/AJR.14.12676. PMID: 25539248. Evidence category: D. Evidence label: Technical. Practical technical/pattern-recognition reference for necrotizing infection and its mimics.
10. Schmid MR, Kossmann T, Duewell S. Differentiation of necrotizing fasciitis and cellulitis using MR imaging. AJR Am J Roentgenol. 1998;170(3):615–620. DOI: 10.2214/ajr.170.3.9490940. PMID: 9490940. Evidence category: D. Evidence label: Technical. Early technical description of MRI signal criteria distinguishing necrotizing fasciitis from cellulitis.

E. Landmark Historical References

11. Rahmouni A, Chosidow O, Mathieu D, Gueorguieva E, Jazaerli N, Radier C, Faivre JM, Roujeau JC, Vasile N. MR imaging in acute infectious cellulitis. Radiology. 1994;192(2):493–496. DOI: 10.1148/radiology.192.2.8029421. PMID: 8029421. Evidence category: E. Evidence label: Foundational. Early landmark description of MRI appearances in soft-tissue cellulitis, underlying subsequent infective-imaging classification.

End of document — MRI Muscle in Tumors and Infection — Generic Standard Protocol — MRIninja Master Page v1.0 — July 2026